Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNT-ORPHAN-06
- Development stage
- Preclinical
- Lead developer
- Centurion
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CNT-ORPHAN-06 is a small molecule systemic anti-infective therapeutic being developed by Centurion for the treatment of rare or orphan diseases. The drug is characterized by its unique 'lyophilized tablet in capsule' (Lyo-Caps) formulation, a technology designed to improve the stability and dissolution profile of the active pharmaceutical ingredient. This formulation approach is particularly beneficial for drugs that are sensitive to moisture or heat during traditional manufacturing processes. CNT-ORPHAN-06 is currently in the development pipeline at Centurion, targeting unmet needs in the systemic anti-infective space for orphan indications.
Beyond the preview
Go deeper on CNT-ORPHAN-06.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNT-ORPHAN-06.